| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
NET LOSS ATTRIBUTABLE TO AGEX | ||||||||
-12,208 | -12,154 | -12,629 | -11,559 | -10,400 | -7,502 | 0 | 0 | 0 |
Net loss attributable to noncontrolling interest | ||||||||
-187 | -230 | -288 | -266 | -221 | -229 | 0 | 0 | 0 |
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: | ||||||||
Gain on sale of equity method investment in Ascendance | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Acquired in-process research and development | ||||||||
- | - | - | - | - | 800 | 0 | 0 | 0 |
Depreciation expense | ||||||||
204 | 91 | 48 | 55 | 53 | 58 | 0 | 0 | 0 |
Amortization of intangible assets | ||||||||
559 | 558 | 559 | 542 | 509 | 477 | 0 | 0 | 0 |
Amortization of right-of-use asset | ||||||||
0 | - | - | - | - | - | - | - | - |
Amortization of debt issuance cost | ||||||||
0 | - | - | - | - | - | - | - | - |
Stock-based compensation | ||||||||
1,686 | 1,907 | 2,284 | 1,969 | 1,621 | 1,285 | 0 | 0 | 0 |
Stock-based compensation allocated from Lineage | ||||||||
- | - | - | - | - | 184 | 0 | 0 | 0 |
Subsidiary stock-based compensation | ||||||||
- | - | - | - | - | 4 | 0 | 0 | 0 |
Income tax provision | ||||||||
- | - | - | - | 0 | - | - | - | - |
Foreign currency remeasurement gain (loss) and other | ||||||||
-52 | -76 | 0 | 0 | 0 | - | - | - | - |
Changes in operating assets and liabilities: | ||||||||
Accounts and grants receivable, net | ||||||||
185 | 232 | 43 | 84 | 152 | 24 | 0 | 0 | 0 |
Prepaid expenses and other current assets | ||||||||
-732 | -473 | -212 | -232 | 254 | 219 | 0 | 0 | 0 |
Accounts payable and accrued liabilities | ||||||||
715 | 169 | 726 | 619 | 314 | 648 | 0 | 0 | 0 |
Related party payables | ||||||||
41 | -68 | 171 | -43 | 30 | -128 | 0 | 0 | 0 |
Insurance premium liability | ||||||||
0 | - | - | - | - | - | - | - | - |
Deferred revenues and other current liabilities | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Deferred revenues | ||||||||
- | - | - | - | - | - | - | - | 0 |
Other current liabilities | ||||||||
- | - | - | - | - | - | - | - | 0 |
Net cash used in operating activities | ||||||||
-9,606 | -10,160 | -9,795 | -8,929 | -8,608 | -7,995 | 0 | 0 | 0 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Proceeds from the sale of equity method investment in Ascendance | ||||||||
- | - | - | - | - | 3,215 | 0 | 0 | 0 |
Purchase of in-process research and development | ||||||||
- | - | - | - | - | 1,872 | 0 | 0 | 0 |
Purchase of equipment and other | ||||||||
642 | 641 | 346 | 117 | 23 | 21 | 0 | 0 | 0 |
Net cash used in investing activities | ||||||||
-362 | -361 | -63 | -1,261 | -1,090 | 1,327 | 0 | 0 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from sale of warrants | ||||||||
- | - | - | - | - | 1,000 | 0 | 0 | 0 |
Proceeds from exercise of warrants | ||||||||
- | 4,500 | 0 | 0 | 0 | - | - | - | - |
Draw down on loan facility from Juvenescence | ||||||||
0 | - | - | - | - | - | - | - | - |
Repayment of financing lease liability | ||||||||
0 | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||||
1,950 | 6,265 | 4,978 | 4,754 | 9,763 | 6,000 | 0 | 0 | 0 |
Effect of exchange rate changes on cash and cash equivalents | ||||||||
0 | - | - | - | - | - | - | - | - |
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||||
NET INCREASE IN CASH AND CASH EQUIVALENTS | ||||||||
- | - | - | - | - | - | - | - | 0 |